A pioneering study is exploring a novel method to enhance the efficacy of CAR T-cell therapy, a groundbreaking treatment for certain cancers. Researchers propose that by stiffening cancer cells prior to treatment, the therapy could become even more potent, potentially improving outcomes for patients battling aggressive tumours.
CAR T-cell therapy involves genetically engineering a patient's own T-cells – a type of immune cell – to recognise and attack cancer cells. While highly successful in treating specific blood cancers like certain leukaemias and lymphomas, its effectiveness can vary, and some patients do not achieve long-term remission. This new research delves into the mechanical properties of cancer cells, suggesting that their physical characteristics play a crucial role in how well they respond to immune attack.
The study, conducted by an international team including scientists from the University of Cambridge, focused on the idea that 'softer' cancer cells might be more adept at evading the immune system. By manipulating these cells to become stiffer, the researchers hypothesise that they become more vulnerable targets for the engineered T-cells. This mechanical alteration could make it harder for cancer cells to escape detection and destruction by the CAR T-cells, leading to a more robust and sustained therapeutic response.
While the full details of the research are still emerging, this concept represents a significant departure from traditional approaches that primarily focus on the biochemical interactions between T-cells and cancer cells. Understanding and manipulating the biophysical environment of tumours could unlock new avenues for treatment. The findings, which are expected to be peer-reviewed, build upon existing knowledge of cell mechanics and their influence on disease progression and immune responses.
If validated in further preclinical models and eventually in human clinical trials, this strategy could offer a crucial advancement for CAR T-cell therapy. It might not only improve response rates but also potentially broaden the types of cancers that can be effectively treated with this revolutionary immunotherapy, offering new hope to patients whose cancers are currently resistant.
Source: University of Cambridge